`Case 1:14-cv-00914-GMS Document 79 *SEALED* Filed 01/29/16 Page 1of4 PagelD #:
`550
`
`IN THE UNITED STATES DISTRICT COURT
`
`FOR THE DISTRICT OF DELAWARE
`
`CUBIST PHARMACEUTICALS, INC.,
`
`Plaintiff,
`
`v.
`
`FRESENIUS KABI USA, LLC,
`
`Defendant.
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`C.A. No. 14-914-GMS
`
`CONFIDENTIAL-(cid:173)
`FILED UNDER SEAL
`
`CONSENT JUDGMENT
`
`Jack B. Blumenfeld (No. 1014)
`Maryellen Noreika (No. 3208)
`MORRIS, NICHOLS, ARSHT & TuNNELL LLP
`1201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@mnat.com
`mnoreika@mnat.com
`Attorneys for Plaintiff Cubist
`Pharmaceuticals, Inc.
`
`Karen E. Keller (No. 4489)
`Jeffrey T. Castellano (#4837)
`SHAW KELLER LLP
`300 Delaware Avenue, Suite 1120
`Wilmington,- DE 19802
`(302) 298-0700
`kkeller@shawkeller.com
`jcastellano@shawkeller.com
`Attorneys for Defendant Fresenius Kabi USA,
`LLC
`
`OF COUNSEL:
`William F. Lee
`Lisa J. Pirozzolo
`Emily R. Whelan
`Sean K. Thompson
`Ryann M. Muir
`WILMER CUTLER PICKERING HALE
`ANDDORRLLP
`60 State Street
`Boston, MA 02109
`(617) 526-6000
`
`Dated: January 29, 2016
`
`OF COUNSEL:
`Elizabeth J. Holland
`Robert V. Cerwinski
`·Daniel P. Margolis
`Linnea P. Cipriano
`Aviv Zalcenstein
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth A venue
`New York, NY 10018
`(212) 813-8800
`
`FRESENIUS-KABI, Exh. 1043
`FRESENIUS-KABI v. CUBIST
`IPR-2015-01570
`
`1 of 4
`
`
`
`Case 1:14-cv-00914-GMS Document 81 Filed 02/02/16 Page 2 of 4 PageID #: 556
`Case 1:14-cv-00914-GMS Document 79 *SEALED* Filed 01/29/16 Page 2 of 4 PagelD #:
`551
`
`IN THE UNITED STATES DISTRICT COURT
`
`FOR THE DISTRICT OF DELAWARE
`
`CUBIST PHARMACEUTICALS, INC.,
`
`Plaintiff,
`
`v.
`
`FRESENIUS KABI USA, LLC,
`
`Defendant.
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`C.A. No. 14-914-GMS
`
`CONFIDENTIAL-(cid:173)
`FILED UNDER SEAL
`
`CONSENT JUDGMENT
`
`Plaintiff Cubist Pharmaceuticals, Inc. ("Plaintiff') and Defendant Fresenius Kabi USA,
`
`LLC ("Defendant"), by their undersigned counsel, stipulate and agree as follows:
`
`WHEREAS Defendant submitted Abbreviated New Drug Application No. 206077
`
`(together with any amendments or supplements thereto, "Defendant's ANDA") to obtain
`
`approval from the FDA to engage in the commercial manufacture, use and/or sale of the generic
`
`daptomycin injectable product described therein ("Defendant's ANDA Product"); and
`
`WHEREAS Plaintiff represents that it owns Patent No. 6,468,967 (the "'967 Patent"),
`
`Patent No. 6,852,689 (the "'689 Patent"), Patent No. 8,058,238 (the '"238 Patent"), and Patent
`
`No. 8,129,342 (the '"342 Patent"); and
`
`WHEREAS Plaintiff represents that it holds approved New Drug Application No. 21572
`
`for CUBICIN® injectable, IV (infusion), 500 mg/vial, which contains the active ingredient
`
`daptomycin; and
`
`WHEREAS Plaintiff has asserted in Cubist Pharmaceuticals, Inc., v. Fresenius Kabi
`
`USA, LLC, C.A. No. 14-914-GMS (D. Del.) ("this Litigation'.') that the filing of Defendant's
`
`ANDA infringes (directly or indirectly) and/or the commercial manufacture, use, offer for sale,
`
`sale and/or importation of Defendant's ANDA Product would infringe (directly or indirectly)
`
`2 of 4
`
`2 of 4
`
`
`
`Case 1:14-cv-00914-GMS Document 81 Filed 02/02/16 Page 3 of 4 PageID #: 557
`Case 1:14-cv-00914-GMS Document 79 *SEALED* Filed 01/29/16 Page 3 of 4 PagelD #:
`552
`
`claims 91, 98, and 187 ofthe '238 Patent, claims 23 and 53 of the '342 Patent, claims 16-17 and
`
`34-35 of the '967 Patent, and claims 51-52 of the '689 Patent (collectively the "Asserted
`
`Claims"); and
`
`WHEREAS the Court in Cubist Pharmaceuticals, Inc. v. Hospira, Inc., No. 12-CV-
`
`00367 (the "Hospira Action") issued a Memorandum Opinion and Judgment after trial holding
`
`that all of the Asserted Claims are invalid (Hospira Judgment); and
`
`WHEREAS Plaintiff appealed the Hospira Judgment to the U.S. Court of Appeals for the
`
`Federal Circuit in Cubist Pharmaceuticals, Inc. v. Hospira, Inc., Nos. 2015-1197, -1204, -1259
`
`(the "Hospira Appeal"); and
`
`WHEREAS the Federal Circuit has affirmed in the Hospira Appeal that the Asserted
`
`Claims are invalid;
`
`Now, THEREFORE, Plaintiff and Defendant consent to the entry of judgment as follows:
`
`1.
`
`2.
`
`The Asserted Claims are invalid;
`
`Plaintiffs claims in this Litigation are dismissed with prejudice in their entirety.
`
`MORRIS, NICHOLS, ARSHT & TUNNELL LLP
`
`SHAW KELLER LLP
`
`Isl Jack B. Blumenfeld
`
`Isl Karen E. Keller
`
`Jack B. Blumenfeld (No.1014)
`Maryellen Noreika (No. 3208)
`1201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@mnat.com
`mnoreika@mnat.com
`Attorneys for Plaintiff Cubist
`Pharmaceuticals, Inc.
`
`Karen E. Keller (No. 4489)
`Jeffrey T. Castellano (No. 4837)
`300 Delaware Avenue, Suite 1120
`Wilmington, DE 19802
`(302) 298-0700
`kkeller@shawkeller.com
`jcastellano@shawkeller.com
`Attorneys for Defendant Fresenius Kabi USA,
`LLC
`
`2
`
`3 of 4
`
`3 of 4
`
`
`
`Case 1:14-cv-00914-GMS Document 81 Filed 02/02/16 Page 4 of 4 PageID #: 558
`Case 1:14-cv-00914-GMS Document 79 *SEALED* Filed 01/29/16 Page 4 of 4 PagelD #:
`553
`
`OF COUNSEL:
`William F. Lee
`Lisa J. Pirozzolo
`Emily R. Whelan
`Sean K. Thompson
`Ryann M. Muir
`WILMER CUTLER PICKERING HALE
`ANDDORRLLP
`60 State Street
`Boston, MA 02109
`(617) 526-6000
`
`OF COUNSEL:
`Elizabeth J. Holland
`Robert V. Cerwinski
`Daniel P. Margolis
`Linnea P. Cipriano
`Aviv Zalcenstein
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth A venue
`New York, NY 10018
`(212) 813-8800
`
`3
`
`4 of 4
`
`4 of 4